6.2.3.4. brachytherapy. 6.2.3.4.1. low-dose rate brachytherapy low-dose rate (ldr) bt uses radioactive seeds permanently implanted prostate. patients declining unsuitable ldr monotherapy offered low-risk nccn favourable intermediate-risk good urinary function defined international prostatic symptom score (ipss) < 12 maximum flow rate > 15 ml/min urinary flow tests . rtog ph3 rct compared ldr bt +/- ebrt participants gleason grade 6 psa < 20 gleason grade 7 psa < 10 found addition ebrt resulted increased toxicity improvement freedom progression . patients previous turp undergo bt without increase risk urinary toxicity due attention dose distribution. minimal channel turp recommended, leaving least 1 cm rim prostate tissue around post-turp urethral defect postero-lateral sides prostate least 3-month interval turp bt allow adequate healing [705-708]. available rct comparing rp ldr bt monotherapy closed due poor accrual . outcome data available number large population cohorts mature follow-up [710-714]. biochemical dfs isup grade group 1 patients five ten years reported range 71% 93% 65% 85%, respectively [710-714]. significant correlation shown implanted dose biochemical control . d90 (dose covering 90% prostate volume) > 140 gy leads significantly higher biochemical control rate (psa < 1.0 ng/ml) four years (92 vs. 68%). os benefit adding neoadjuvant adjuvant adt ldr monotherapy . low-dose rate bt combined ebrt nccn unfavourable intermediate-risk pca high-risk patients. external beam rt (total dose 78 gy) compared ebrt (total dose 46 gy) followed ldr bt boost (prescribed dose 115 gy) intermediate-risk high-risk patients ascende-rt randomised trial twelve months adt arms . ldr boost resulted 5-, 7-year 10-year psa pfs increase (89%,86% 85% respectively, compared 84%,75%, 70%) impact distant metastasis os. improvement biochemical control achieved cost increased late grade 3+ gu toxicity (18% compared 8%) 2 treatment related deaths . urinary toxicity mainly development urethral strictures incontinence great care taken treatment planning. 6.2.3.4.2. high-dose rate brachytherapy high-dose rate (hdr) bt uses radioactive source temporarily introduced prostate deliver radiation. technical differences outlined table 6.1.11. use gec (groupe europeen de curietherapie)/estro guidelines strongly recommended . high-dose rate bt delivered single multiple fractions often combined ebrt least 45 gy, conventionally fractionated . retrospective analysis 1641 intermediate high-risk patients demonstrated better distant-metastasis free survival hdr bt boost added 50 – 54 gy ebrt. difference mounted 12% ten years . sr non-rcts data population studies suggest outcomes ebrt plus hdr bt superior ebrt alone . single-centre rct ebrt (55 gy 20 fractions) vs. ebrt (35.75 gy 13 fractions), followed hdr bt (17 gy two fractions 24 hours) reported . 218 patients t1–3 n0m0 pca combination ebrt hdr bt showed significant improvement biochemical disease-free rate (p = 0.04) five ten years (75% 46% compared 61% 39%). however, unexpectedly high rate early recurrences observed ebrt arm alone, even 2 years, possibly due dose lower current standard used . supporting, definitive, evidence benefit hdr boost available trog 03.04 radar trial. multi-centre study upfront radiation dose escalation (non-randomised) dosing options 66, 70, 74 gy ebrt, 46 gy ebrt plus hdr bt boost randomised men locally-advanced pca 6 18 months adt. minimum follow-up ten years hdr boost significantly reduced distant progression, study primary endpoint (sub hr: 0.68, 95% ci: 0.57–0.80; p < 0.0001), compared ebrt alone and, independent duration adt, hdr boost associated increased ipss 3 points 18 months post-treatment resolving three years decreased rectal symptoms compared ebrt . although radiation dose escalation using bt boost provides much higher biological doses, trog 03.04 radar rct srs show adt use independently predicts better outcomes regardless radiation dose intensification . omitting adt may result inferior os based current evidence adt use duration line used delivering ebrt alone. fractionated hdr bt monotherapy offered patients low- intermediate-risk pca, informed results available limited series experienced centres. five-year psa control rates 97.5% 93.5% low- intermediate-risk pca, respectively, reported, late grade 3+ gu toxicity rates < 5% no, minimal, grade 3+ gi toxicity rates . single fraction hdr monotherapy used inferior biochemical control rates compared fractionated hdr monotherapy . table 6.2.11: difference ldr hdr brachytherapy differences prostate brachytherapy techniqueslow dose rate (ldr)permanent seeds implanteduses iodine-125 (i-125) (most common), palladium-103 (103pd-) cesium-131 isotopesradiation dose delivered weeks monthsacute side effects resolve monthsradiation protection issues patient carershigh dose rate (hdr)temporary implantationiridium-192 (ir-192) isotope introduced implanted needles cathetersradiation dose delivered minutesacute side effects resolve weeksno radiation protection issues patient carers